Expression and clinical significance of EFhd1 in patients with non-small cell lung cancer

doi:10.3877/cma.j.issn.1674-6902.2019.05.008

Abstract

Abstract:

Objective

To investigate the expression of EFhd1 and its potential value as a prognostic indicator of survival in the patients with primary non-small cell lung cancer (NSCLC).

Methods

A total of 178 NSCLC tissue specimens and 51 paracancerous tissue specimens were collected from 178 NSCLC surgical patients from January 2004 to April 2011 in the Cardiothoracic Surgery Department of the Affiliated Hospital of Nantong University. The clinical data and follow-up data were collected, too. Immunohistochemical analysis with tissue microarray was used to characterize the expression of EFhd1 in the NSCLC tissues. The relationship between the EFhd1 expression and the clinical characteristics and prognosis was determined by statistical analysis.

Results

The level of EFhd1 expression was higher in the NSCLC tissues than in the paracancerous tissues (P<0. 05). The EFhd1 expression in the NSCLC tissues was related to the T staging (P<0.05). Univariate analysis revealed that TNM stage, T stage and N stage were associated with the prognosis of NSCLC (P<0.01). Kaplan Meier survival and Cox regression analyses revealed that the higher level of EFhd1 expression (P=0.037) and later stage grouping by TNM (P=0.001) were independent factors predicting poor prognosis for the patients with NSCLC.

Conclusion

The level of EFhd1 expression in the NSCLC tissues is significantly higher than that in the adjacent tissues. Our finding provides the first evidence that the higher level of EFhd1 expression is associated with the poor prognosis of the patients with NSCLC.

Key words: EFhd1, Non-small cell lung cancer, Immunohistochemistry, Clinicopathologic parameters, Prognosis

Liqin Xu, Mengyuan Lyu, Jian Feng. Expression and clinical significance of EFhd1 in patients with non-small cell lung cancer[J]. Chinese Journal of Lung Diseases(Electronic Edition), 2019, 12(05): 573-578.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhfbjbzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-6902.2019.05.008

https://zhfbjbzz.cma-cmc.com.cn/EN/Y2019/V12/I05/573

Figures/Tables 4

References 25

1	Pabani A, Butts CA. Current landscape of immunotherapy for the treatment of metastatic non-small-cell lung cancer.[J]. Curr Oncol, 2018, 25(S1): S94-S102.
2	Jemal A, Bray F, Center MM, et al. Global cancer statistics[J]. CA Cancer J Clin, 2011, 61(2): 69-90.
3	Osmani L, Askin F, Gabrielson E, et al. Current WHO guidelines and the critical role of immunohistochemical markers in the subclassification of non-small cell lung carcinoma (NSCLC): Moving from targeted therapy to immunotherapy[J]. Semin Cancer Biol, 2018, 52(Pt 1): 103-109.
4	Khanna P, Blais N, Gaudreau PO, et al. Immunotherapy comes of age in lung cancer[J]. Clin Lung Cancer, 2017, 18: 13-22.
5	Siegel RL, Miller KD, Jemal A. Cancer statistics，2015[J]. CA Cancer J Clin, 2015, 65(1): 5-39.
6	Yang JJ. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma [J]. N Engl J Med, 2009, 361(10): 947-957.
7	Solomon BJ, Mok T, Kim DW, et al. First-Line crizotinib versus chemotherapy in ALK-Positive.lung cancer[J]. N．Engl.J.Med, 2014, 371(23): 2167-2177.
8	Berridge M, Lipp P, Bootman M. Calcium signaling[J]. Curr Biol, 1999, 9(5): R157-159.
9	Haynes WM. CRC handbook of chemistry and physics[J]. CRC press, 2014, 17(6): 342-351.
10	Belgacem YH, Borodinsky LN. Sonic hedgehog signaling is decoded by calcium spike activity in the developing spinal cord[J]. Proc Natl Acad Sci U S A, 2011, 108(11): 4482-4487.
11	Kadio B, Yaya S, Basak A, et al. Calcium role in human carcinogenesis：a comprehensive analysis and critical review of literature[J]. Cancer Metastasis Rev, 2016, 35(3): 391-411.
12	Hajnóczky G, Booth D, Csordás G, et al. Reliance of ER-mitochondrial calcium signaling on mitochondrial EF-hand Ca²⁺ binding proteins: Miros, MICUs, LETM1 and solute carriers[J]. Curr. Opin. Cell Biol, 2014, 29(5): 133-141.
13	Mootha V．K, Bunkenborg J, Olsen J．V, et al. Integrated analysis of protein composition, tissue diversity, and gene regulation in mouse mitochondria[J]. Cell, 2003, 11(5): 629-640.
14	Dütting S, Brachs S, Mielenz D. Fraternal twins: Swiprosin-1/EFhd2 and Swiprosin-2/EFhd1, two homologous EF-hand containing calcium binding adaptor proteins with distinct functions[J]. Cell Commun Signal, 2011, 9(2): 215-231.
15	Lucas B, Grigo K, Erdmann S, et al. HNF4 alpha reduces proliferation of kidney cells and affects genes deregulated in renal cell carcinoma[J]. Oncogene, 2005, 24(3): 6418-6431.
16	Grigo K, Wirsing A, Lucas B, et al. HNF4 alpha orchestrates a set of 14 genes to down-regulate cell proliferation in kidney cells[J]. Biol Chem, 2008, 389: 179-187.
17	Davidson B, Stavnes HT, Risberg B, et al. Gene expression signatures differentiate adenocarcinoma of lung and breast origin in effusions[J]. Human Pathology, 2012, 43(7): 684-694.
18	Mandruzzato S, Callegaro A, Turcatel G, et al. A gene expression signature associated with survival in metastatic melanoma[J]. J Transl Med, 2006, 4(3): 50-63.
19	Hurt EM, Thomas SB, Peng B, et al. Molecular consequences of SOD2 expression in epigenetically silenced pancreatic carcinoma cell lines[J]. Cancer, 2007, 9(7): 1116-1123.
20	Konstantinovsky S, Smith Y, Zilber S. Breast carcinoma cells in primary tumors and effusions have different gene array profiles[J]. J Oncol, 2010, 2(10): 969-984.
21	Takane K, Midorikawa Y, Yagi K, et al. Aberrant promoter methylation of PPP1R3C and EFhd1 in plasma of colorectal cancer patients[J]. Cancer Med, 2014, 3(5): 1235-1245.
22	Urbanczyk S, Stein M, Schuh W, et al. Regulation of Energy Metabolism during Early B Lymphocyte Development[J]. Molecular Sciences, 2018, 22(4): 6418-6431.
23	Stein M, Dütting S, Mougiakakos D, et al. A defined metabolic state in pre B cells governs B-cell development and is counterbalanced by Swiprosin-2/EFhd1[J]. Cell Death Differ, 2017, 24(6): 1239-1252.
24	Bianchi K, Vandecasteele G, Carli C, et al. Regulation of Ca²⁺ sig-nalling and Ca²⁺-mediated cell death by the transcriptional coactivator PGC-1α[J]. Cell Death Differ, 2006, 13(4): 586-596.
25	Zhou Z, Zhou J, Du Y. Estrogen receptor alpha interacts with mitochondrial protein HADHB and affects beta-oxidation activity[J]. Mol Cell Proteomics, 2012, 11(7): M111.011056.

临床资料		EFhd1表达		χ²值	P值
临床资料		低表达	高表达	χ²值	P值
性别
	女	25(24.8)	16(20.8)	0.389	0.533
	男	76(75.2)	61(79.2)
年龄
	≤60岁	37(36.6)	21(27.3)	1.743	0.187
	>60岁	64(63.4)	56(72.7)
组织学类型
	鳞癌	58(57.4)	38(49.4)	1.910	0.385
	腺癌	27(26.7)	28(36.4)
	其他	16(15.8)	11(14.3)
肿瘤直径
	≤3 cm	51(50.5)	31(40.3)	1.452	0.228
	>3 cm	50(49.5)	46(59.7)
T分期
	T1	31(30.7)	28(36.4)	7.345	0.025
	T2	53(52.5)	46(59.7)
	T3-T4	17(16.9)	3(3.9)
N分期
	N0	45(44.6)	43(55.8)	2.327	0.312
	N1	31(20.7)	20(26.0)
	N2	25(24.8)	14(18.2)
M分期
	M0	100(99.0)	77(100)	0.767	0.381
	M1	1(1.0)	0
分化程度
	未知	23(22.8)	20(26.0)	0.493	0.920
	低	17(16.8)	13(16.9)
	中	57(56.4)	40(51.9)
	高	4(4.0)	4(5.2)
TNM分期
	Ⅰ期	32(31.7)	34(44.2)	4.252	0.236
	Ⅱ期	37(36.6)	27(35.1)
	Ⅲ期	31(30.7)	16(20.8)
	Ⅳ期	1(1.0)	0

临床资料		EFhd1表达		χ²值	P值
临床资料		低表达	高表达	χ²值	P值
性别
	女	25(24.8)	16(20.8)	0.389	0.533
	男	76(75.2)	61(79.2)
年龄
	≤60岁	37(36.6)	21(27.3)	1.743	0.187
	>60岁	64(63.4)	56(72.7)
组织学类型
	鳞癌	58(57.4)	38(49.4)	1.910	0.385
	腺癌	27(26.7)	28(36.4)
	其他	16(15.8)	11(14.3)
肿瘤直径
	≤3 cm	51(50.5)	31(40.3)	1.452	0.228
	>3 cm	50(49.5)	46(59.7)
T分期
	T1	31(30.7)	28(36.4)	7.345	0.025
	T2	53(52.5)	46(59.7)
	T3-T4	17(16.9)	3(3.9)
N分期
	N0	45(44.6)	43(55.8)	2.327	0.312
	N1	31(20.7)	20(26.0)
	N2	25(24.8)	14(18.2)
M分期
	M0	100(99.0)	77(100)	0.767	0.381
	M1	1(1.0)	0
分化程度
	未知	23(22.8)	20(26.0)	0.493	0.920
	低	17(16.8)	13(16.9)
	中	57(56.4)	40(51.9)
	高	4(4.0)	4(5.2)
TNM分期
	Ⅰ期	32(31.7)	34(44.2)	4.252	0.236
	Ⅱ期	37(36.6)	27(35.1)
	Ⅲ期	31(30.7)	16(20.8)
	Ⅳ期	1(1.0)	0

临床资料		单因素分析			多因素分析
临床资料		HR	P值	95%CI	HR	P值	95%CI
性别		0.986	0.942	0.668～1.454
	女 vs.男
年龄		1.096	0.616	0.766～1.567
	≤60 vs. >60
T分期		1.465	0.006	1.113～1.928
	T1 vs. T2 vs.T3-T4
N分期		1.689	0.001	1.387～2.055
	N0 vs. N1 vs. N2
M分期		0.879	0.898	0.123～6.290
	M0 vs. M1
临床分期		1.725	0.001	1.420～2.097	1.824	0.001	1.359～2.449
	Ⅰ期 vs. Ⅱ期 vs. Ⅲ-Ⅳ期
组织类型		0.954	0.667	0.770 ～1.182
	鳞癌 vs.腺癌 vs.其它
分化程度		0.917	0.410	0.746～1.127
	低 vs.中 vs.高vs.未知
肿瘤直径		1.213	0.322	0.822～1.790
	≤3 cm vs. >3 cm
EFhd1表达程度		1.328	0.147	0.950～1.948	1.679	0.037	1.031～2.734
	低表达 vs.高表达

临床资料		单因素分析			多因素分析
临床资料		HR	P值	95%CI	HR	P值	95%CI
性别		0.986	0.942	0.668～1.454
	女 vs.男
年龄		1.096	0.616	0.766～1.567
	≤60 vs. >60
T分期		1.465	0.006	1.113～1.928
	T1 vs. T2 vs.T3-T4
N分期		1.689	0.001	1.387～2.055
	N0 vs. N1 vs. N2
M分期		0.879	0.898	0.123～6.290
	M0 vs. M1
临床分期		1.725	0.001	1.420～2.097	1.824	0.001	1.359～2.449
	Ⅰ期 vs. Ⅱ期 vs. Ⅲ-Ⅳ期
组织类型		0.954	0.667	0.770 ～1.182
	鳞癌 vs.腺癌 vs.其它
分化程度		0.917	0.410	0.746～1.127
	低 vs.中 vs.高vs.未知
肿瘤直径		1.213	0.322	0.822～1.790
	≤3 cm vs. >3 cm
EFhd1表达程度		1.328	0.147	0.950～1.948	1.679	0.037	1.031～2.734
	低表达 vs.高表达

[1]	Siping Zhang, Wei Liu, Pengcheng Ma. Therapeutic effects of lower extremity mild varus alignment after total knee arthroplasty [J]. Chinese Journal of Joint Surgery(Electronic Edition), 2023, 17(06): 808-817.
[2]	Yuezhou Li, Kongxi Zhang, Xiaohong Li, Zhonghua Shang. Prognostic significance of PUM in gastric carcinoma based on bioinformatics analysis [J]. Chinese Archives of General Surgery(Electronic Edition), 2023, 17(06): 426-432.
[3]	Jun Zhang, Zai Luo, Mingyu Duan, Zhengjun Qiu, Chen Huang. Research progress of prognostic prediction models for gastric cancer [J]. Chinese Archives of General Surgery(Electronic Edition), 2023, 17(06): 456-461.
[4]	Qian Yang, Cuifang Li, Wanqiu Zhang. Analysis of short-term and long-term prognosis and influencing factors of primary liver cancer with spontaneous ruptured hemorrhage after emergency TACE surgery [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2024, 18(01): 33-36.
[5]	Yansong Li, Huimin Feng, Mingchao Liu, Zepeng Liu, Qiuxia Jiang. Expression and clinical significance of STIP1 in triple negative breast cancer [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2024, 18(01): 52-56.
[6]	Bing Pan, Shaocheng Lyu, Xin Zhao, Lixin Li, Ren Lang, Qiang He. Effect of number of dissected lymph nodes on efficacy of pancreaticoduodenectomy for distal cholangiocarcinoma [J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2023, 12(06): 608-612.
[7]	Qikun Zhang, Fuchao Shang, Qi Li, Guangming Li, Menglong Wang. Survival benefit of combined splenectomy in patients with liver cancer complicated with portal hypertension after radical resection [J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2023, 12(06): 613-618.
[8]	Wenhua Zhang, Cui Tao, Tiansong Hu. Clinicopathological characteristics of pedunculated hepatocellular carcinoma in different sites and its effects on postoperative intrahepatic recurrence and prognosis [J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2023, 12(06): 651-655.
[9]	Guangjun Zhong, Chunhua Liu, Wansen Zhu, Xiaolei Xu, Zhaojun Wang. Application of conventional MRI combined with different scanning sequences in preoperative staging diagnosis, chemotherapy efficacy and prognosis evaluation of gastric cancer [J]. Chinese Journal of Digestion and Medical Imageology(Electronic Edition), 2023, 13(06): 378-382.
[10]	Baoru Hu, Naijian Shang, Di Gao. DCE-MRI and DWI findings of advanced hepatocellular carcinoma and their correlation with prognosis after immunotherapy [J]. Chinese Journal of Digestion and Medical Imageology(Electronic Edition), 2023, 13(06): 399-403.
[11]	Ping Lu, Jian Zou. Value of dynamic changes in coagulation and fibrinolytic markers in evaluating the prognosis of patients with acute pancreatitis [J]. Chinese Journal of Digestion and Medical Imageology(Electronic Edition), 2023, 13(06): 427-432.
[12]	Yongsheng Li, Jiahe Sun, Shuwei Guo, Yikang Lu, Hongzhou Liu. Short-term postoperative complications and their influencing factors in elderly patients with colorectal cancer [J]. Chinese Journal of Clinicians(Electronic Edition), 2023, 17(9): 962-967.
[13]	Jun Wang, Kunpeng Liu, Lan Yao, Hua Zhang, Yue Wei, Libin Suo, Jun Chen, chengli Miao, Chenghua Luo. Retrospective analysis of anesthesia management of massive transfusion patients undergoing retroperitoneal tumor resection [J]. Chinese Journal of Clinicians(Electronic Edition), 2023, 17(08): 844-849.
[14]	Ruixue Yue, Lingxin Kong, Xin Hao, Jinqiang Yang, Meng Han, Guozhong Cui, Jianjun Wang, Zhisheng Zhang, Fanting Kong, Wei Zhang, Wenbo He, Xianqiao Li, Xinping Zhou, Donghong Xu, Chongzhu Hu. HER2 protein expression levels predict efficacy of neoadjuvant therapy in breast cancer: A real-world study [J]. Chinese Journal of Clinicians(Electronic Edition), 2023, 17(07): 765-770.
[15]	Libin Suo, Kunpeng Liu, Lan Yao, Hua Zhang, Yue Wei, Jun Wang, Jun Chen, Chengli Miao, Chenghua Luo. Key points of anesthesia management and prognostic factors in patients undergoing primary retroperitoneal paraganglioma resection [J]. Chinese Journal of Clinicians(Electronic Edition), 2023, 17(07): 771-776.

Please choose a citation manager

Content to export